Bioanalysis or pharmacokinetic/pharmacodynamics (PK/PD) information provides some of the most fundamental information necessary in the development of mAbs, such as drug efficacy and toxicity. Absorption, distribution, metabolism and excretion (ADME) analysis determines how these four-criteria influence performance and pharmacological activity, such as drug distribution in plasma and tissue. Bioanalysis also provides information to determine dosing levels.
The ELISA method which is commonly used to measure drug concentration in blood has critical issues with the effectiveness and efficiency. LCMS overcomes the difficulties of the ELISA method with selectivity and sensitivity. To further simplify and streamline the LCMS workflow for antibody bioanalysis, Shimadzu developed an innovative nano-technology based nSMOLTM Antibody Bioanalysis platform for the selective proteolysis of the Fab region of antibody drugs to increase the detection sensitivity of surrogate peptides in CDR regions that can be accurately quantified via MRM measurements using a triple quadrupole high performance liquid chromatograph mass spectrometer.
- nSMOL e-Book
- LCMS Bioanalysis of Antibody Drugs Using Fab-selective Proteolysis "nSMOL Method"
- LCMS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL - Trastuzumab analysis
- LCMS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL- Part 2 - Bevacizumab analysis
- LCMS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL - Part 3 - Nivolumab analysis
- LCMS Bioanalysis of Antibody Drugs Using FabSelective Proteolysis nSMOL - Part 4 - Multiplex Analysis
- The Benefits of Nano-Surface and Molecular-Orientation Limited (nSMOL) Proteolysis for Monoclonal Antibody Drug Analysis